UroGen Pharma (URGN) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
UroGen Pharma (URGN) has outperformed Xeris Biopharma (XERS) over the past year, gaining 124.3% versus a gain of 28.0%. Over five years, XERS leads with a +424.0% price change compared with +116.4% for URGN. Xeris Biopharma is the larger company by market cap ($1.91 billion vs $1.80 billion), about 1.1 times the size.
On valuation, UroGen Pharma trades at a lower forward P/E (13.2x vs 28.3x for Xeris Biopharma). Xeris Biopharma converts more of its revenue into profit, with a net margin of 0.2% versus -139.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | URGN | XERS |
|---|---|---|
| Share price | $36.83 | $10.48 |
| Market cap | $1.80B | $1.91B |
| 1-day change | -0.41% | +2.85% |
| YTD return | +57.26% | +33.50% |
| 1-year return | +124.30% | +27.96% |
| 5-year return | +116.39% | +424.00% |
| Forward P/E | 13.18 | 28.32 |
| EPS (TTM) | $-1.96 | $-0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $109.79M | $291.85M |
| Revenue growth (YoY) | +21.45% | +43.72% |
| Net income (latest FY) | $-153.49M | $554.00K |
| Gross margin | 88.66% | 85.41% |
| Operating margin | -113.73% | 8.53% |
| Net margin | -139.81% | 0.19% |
| 52-week high | $50.81 | $11.33 |
| 52-week low | $15.86 | $5.25 |
| Distance from 52-week high | -27.51% | -7.50% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +62.91% | +22.71% |
| Average volume | 849.01K | 2.18M |
| Shares outstanding | 48.88M | 182.32M |
| Employees | 300 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed XERS by 96.3 percentage points over the past year.
- Xeris Biopharma is more profitable, keeping 0.2 cents of every revenue dollar as net income versus -139.8 cents for UroGen Pharma.
- Xeris Biopharma grew revenue faster in its latest fiscal year (+43.72% vs +21.45%).
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
URGN vs XERS FAQ
Which is bigger, UroGen Pharma or Xeris Biopharma?
Xeris Biopharma (XERS) is larger, with a market capitalization of $1.91B compared with $1.80B for UroGen Pharma (URGN).
Which stock has performed better over the past year, URGN or XERS?
URGN returned +124.30% over the past 12 months, compared with +27.96% for XERS (price return, excluding dividends). Past performance does not predict future results.
Are UroGen Pharma and Xeris Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.